Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-T

Sangamo Therapeutics

Status and phase: Terminated; Phase 1

Conditions: HIV-1-infection

Treatments: Drug: There are no disallowed treatments

Study type: Observational

Funder types: Industry

Identifiers

NCT04201782

SB-728-1003

Details and patient eligibility

About

Long-term follow-up of HIV-infected subjects who received SB-728-T or SB-728mR-T. Enrolling subjects will be followed for a total of 12 years.

Full description

Subjects infected with HIV who have received therapy with SB-728-T or SB-728mR-T will be eligible to participate in this trial. There will be no treatment in this long-term follow-up study. Subjects who choose to enroll into this extension study will be evaluated for a total of 12 years.

Enrollment: 38 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Subjects who have, in previous Sangamo clinical trial received SB-728-T or SB-728mR-T, autologous T-cells genetically modified at the CCR5 gene by zinc finger nucleases and give consent to participate in the long-term follow-up study.

Exclusion criteria

There are no exclusion criteria for this study.

Trial design

38 participants in 1 patient group

Cohort 1

Description:

Long-term follow-up of HIV-infected subjects who received SB-728-T or SB-728mR-T in a previous trial.

Treatment:

Drug: There are no disallowed treatments